Synthesis and in vitro/in vivo antibacterial activity of oxazolidinones having thiocarbamate at C-5 on the A-ring and an amide- or urea-substituted [1,2,5]triazepane or [1,2,5]oxadiazepane as the C-ring
摘要:
Oxazolidinones bearing a seven-membered [1,2,51triazepane or [1,2,51oxadiazepane heterocycle substituted with an amide or urea functionality as the C-ring and having a [1,2,3]triazole, a thiocarbamate, an isoxazole-3-ylamino, or a thioacetamide C-5 side chain unit on the A-ring instead of the typical acetamide were synthesized and their in vitro antibacterial activities towards various pathogens were evaluated. Several derivatives exhibited potent in vitro antibacterial activity toward not only Grampositive, but also Gram-negative and linezolid-resistant pathogens. The in vivo therapeutic effects of amide 11a and ureas 16e, 17a were 2- to 3-fold greater than that of linezolid in a systemic mouse infection model treated by intravenous administration. Furthermore, compounds 11a and 17a showed lower monoamine oxidase (MAO)-inhibitory activity than our previously reported potent oxazolidinone antibacterials 3a and 3b. (C) 2013 Elsevier Masson SAS. All rights reserved.
The invention provides a novel oxazolidinone derivative represented by the formula (I):
wherein
Ring A is optionally substituted or fused and represents
(A-1) at least 7-membered monocyclic hetero ring containing at least three N atoms; (A-2) at least 6-membered monocyclic hetero ring containing at least two N atoms and at least one O atom; or (A-3) at least 7-membered monocyclic hetero ring containing at least two N atoms and at least one S atom;
X1 is a single bond, -O-, -S-, -NR2-, -CO-, -CS-, - CONR3-, -NR4CO-, -SO2NR5-, and -NR6SO2- (wherein R2 - R6 are independently hydrogen or lower alkyl), or lower alkylene or lower alkenylene in which one of the preceding groups may intervene;
Ring B is optionally substituted carbocycle or optionally substituted heterocycle;
R1 is hydrogen, or an organic residue which is able to bind to the 5-position of oxazolidinone ring in oxazolidinone antimicrobial agent,
and an antibacterial agent containing the same.
本发明提供了一种由式 (I) 表示的新型噁唑烷酮衍生物:
其中
环 A 被任选取代或融合,并代表
(A-1) 至少含有三个 N 原子的 7 元单环杂环; (A-2) 至少含有两个 N 原子和至少一个 O 原子的 6 元单环杂环;或 (A-3) 至少含有两个 N 原子和至少一个 S 原子的 7 元单环杂环;
X1为单键、-O-、-S-、-NR2-、-CO-、-CS-、-CONR3-、-NR4CO-、-SO2NR5-和-NR6SO2-(其中 R2 - R6 独立地为氢或低级烷基),或低级亚烷基或低级亚烯基,其中可介入前述基团之一;
环 B 是任选取代的碳环或任选取代的杂环;
R1 是氢,或能够与恶唑烷酮类抗菌剂中恶唑烷酮环 5 位结合的有机残基、
以及含有相同成分的抗菌剂。
Novel Compound Having Heterocyclic Ring
申请人:Suzuki Hideyuki
公开号:US20090299059A1
公开(公告)日:2009-12-03
The invention provides a novel oxazolidinone derivative represented by the formula (I):
wherein
Ring A is optionally substituted or fused and represents
(A-1) at least 7-membered monocyclic hetero ring containing at least three N atoms; (A-2) at least 6-membered monocyclic hetero ring containing at least two N atoms and at least one O atom; or (A-3) at least 7-membered monocyclic hetero ring containing at least two N atoms and at least one S atom;
X
1
is a single bond, —O—, —S—, —NR
2
—, —CO—, —CS—, —CONR
3
—, —NR
4
CO—, —SO
2
NR
5
—, and —NR
6
SO
2
— (wherein R
2
-R
6
are independently hydrogen or lower alkyl), or lower alkylene or lower alkenylene in which one of the preceding groups may intervene;
Ring B is optionally substituted carbocycle or optionally substituted heterocycle;
R
1
is hydrogen, or an organic residue which is able to bind to the 5-position of oxazolidinone ring in oxazolidinone antimicrobial agent,
and an antibacterial agent containing the same.